L-Alanine
|
Basic information |
| Metabolite name | L-Alanine |
 | HMDB0000161 |
 |
C00041 |
 |
5950 |
| Synonyms | Ala; |
| No. of studies | 100 |
|
Basic information |
| Metabolite name | L-Alanine |
| HMDB0000161 |
|
C00041 |
|
5950 |
| Synonyms | Ala; |
| No. of studies | 100 |
|
Relationship between L-Alanine and depression (count: 100) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M002 | Type1 | CUMS group vs. control group | Cerebral cortex | Sprague-Dawley rat | Down |
| Study M004 | Type2 | CUMS + amitriptyline group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M006 | Type1 | depressed group vs. control group | Plasma | Human | Up |
| Study M013 | Type3 | paroxetine group vs. control group | Hippocampus | DBA/2OlaHsd mouse | Up |
| Study M017 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M018 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Down |
| Study M018 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M019 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M021 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M022 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M030 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M032 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M032 | Type2 | CUMS + middle dose of genipin group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M032 | Type2 | CUMS + high dose of genipin group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M032 | Type2 | CUMS + venlafaxine group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M033 | Type3 | paroxetine group vs. control group | Hippocampus | DBA/2OlaHsd mouse | Down |
| Study M035 | Type1 | depressed suicide attempters group vs. control group | Plasma | Human | Down |
| Study M036 | Type1 | MDD group vs. control group | Urine | Human | Up |
| Study M040 | Type1 | MDD group vs. control group | Plasma | Human | Up |
| Study M043 | Type1 | chronic hepatitis B patients with MDD group vs. without MDD group | Urine | Human | Down |
| Study M047 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M047 | Type2 | CUMS + middle dose of genipin group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M049 | Type2 | xiaoyansan treatment 8-week vs. baseline | Urine | Human | Down |
| Study M055 | Type1 | CUMS group vs. control group | Liver | Sprague-Dawley rat | Up |
| Study M055 | Type2 | CUMS + low dose of genipin group vs. CUMS group | Liver | Sprague-Dawley rat | Down |
| Study M055 | Type2 | CUMS + middle dose of genipin group vs. CUMS group | Liver | Sprague-Dawley rat | Down |
| Study M059 | Type1 | depressed group vs. control group | Plasma | Human | Down |
| Study M059 | Type2 | Xiaoyaosan-treated depressed group 8-week vs. baseline | Plasma | Human | Up |
| Study M064 | Type1 | CUMS group vs. control group | Cecum | Sprague-Dawley rat | Up |
| Study M064 | Type2 | CUMS + Xiaoyaosan group vs. CUMS group | Cecum | Sprague-Dawley rat | Down |
| Study M064 | Type2 | CUMS + fluoxetine group vs. CUMS group | Cecum | Sprague-Dawley rat | Down |
| Study M065 | Type1 | depressed group vs. control group | Plasma | Human | Up |
| Study M082 | Type3 | medium dose of DG group vs. control group | Hippocampus | C57BL/6J mouse | Down |
| Study M082 | Type3 | venlafaxine group vs. control group | Hippocampus | C57BL/6J mouse | Down |
| Study M084 | Type1 | melancholic depressed group vs. control group | Plasma | Human | Up |
| Study M087 | Type2 | esketamine group 2-h vs. baseline | Plasma | Human | Down |
| Study M090 | Type1 | depressed group vs. control group | Urine | Human | Up |
| Study M090 | Type2 | depressed group 6-week treatment vs. baseline | Urine | Human | Down |
| Study M092 | Type1 | LPS group vs. control group | Prefrontal cortex | CD-1 mouse | Up |
| Study M093 | Type1 | depression group vs. control group | Serum | Human | Up |
| Study M093 | Type2 | paroxetine group vs. baseline | Serum | Human | Down |
| Study M097 | Type1 | depressed women group vs. control women group | Urine | Human | Up |
| Study M097 | Type1 | depressed men group vs. control men group | Urine | Human | Up |
| Study M100 | Type1 | CS group vs. control group | Hippocampus | Wistar rat | Down |
| Study M102 | Type1 | severe MDD group vs. control group | Urine | Human | Up |
| Study M1048 | Type1 | juvenile high-fat diet group vs. juvenile control group | Brain | CD-1 mouse | Up |
| Study M1048 | Type1 | juvenile high-fat diet group vs. juvenile control group | Plasma | CD-1 mouse | Down |
| Study M1048 | Type1 | adult high-fat diet group vs. adult control group | Liver | CD-1 mouse | Up |
| Study M1048 | Type1 | adult high-fat diet group vs. adult control group | Faece | CD-1 mouse | Up |
| Study M1048 | Type2 | adult high-fat diet + probiotic group vs. adult high-fat diet group | Plasma | CD-1 mouse | Down |
| Study M1048 | Type2 | adult high-fat diet + probiotic group vs. adult high-fat diet group | Brain | CD-1 mouse | Up |
| Study M1048 | Type2 | adult high-fat diet + probiotic group vs. adult high-fat diet group | Liver | CD-1 mouse | Up |
| Study M1048 | Type3 | adult probiotic group vs. adult control group | Plasma | CD-1 mouse | Down |
| Study M1048 | Type3 | adult probiotic group vs. adult control group | Liver | CD-1 mouse | Up |
| Study M1048 | Type3 | adult probiotic group vs. adult control group | Brain | CD-1 mouse | Up |
| Study M1048 | Type3 | adult probiotic group vs. adult control group | Faece | CD-1 mouse | Down |
| Study M1056 | Type2 | maternal separation + beraprost group vs. maternal separation group | Serum | Sprague-Dawley rat | Down |
| Study M1057 | Type1 | depression group vs. control group | Serum | Human | Up |
| Study M1061 | Type1 | CUMS group vs. control group | Faece | Sprague-Dawley rat | Up |
| Study M1066 | Type1 | CUMS group vs. control group | Kidney | Sprague-Dawley rat | Up |
| Study M1066 | Type2 | CUMS + Shugan group vs. CUMS group | Kidney | Sprague-Dawley rat | Down |
| Study M1066 | Type2 | CUMS + Xiaoyaosan group vs. CUMS group | Kidney | Sprague-Dawley rat | Down |
| Study M1066 | Type2 | CUMS + Jianpi group vs. CUMS group | Kidney | Sprague-Dawley rat | Down |
| Study M107 | Type1 | Glu group vs. control group | PC12 cell medium | Rat | Down |
| Study M107 | Type1 | Glu group vs. control group | PC12 cell | Rat | Down |
| Study M107 | Type1 | CORT group vs. control group | PC12 cell medium | Rat | Down |
| Study M1074 | Type1 | MDD group vs. control group | Serum | Human | Up |
| Study M1075 | Type1 | CSDS group vs. control group | Serum | C57BL/6J mouse | Up |
| Study M108 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M108 | Type1 | CUMS group vs. control group | Liver | Sprague-Dawley rat | Up |
| Study M108 | Type2 | CUMS + VBBR group vs. CUMS group | Liver | Sprague-Dawley rat | Down |
| Study M108 | Type2 | CUMS + VBBR group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M1090 | Type3 | hyperbaric oxygen treatment group vs. control group | Plasma | BALb/c mouse | Up |
| Study M1102 | Type1 | nitenpyram group vs. control group, male offspring | Faece | ICR mouse | Down |
| Study M111 | Type3 | WT-Scop group vs. WT-Veh group | Plasma | C57BL/6 mouse | Down |
| Study M1143 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M119 | Type1 | LH group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M129 | Type3 | venlafaxine group vs. control group | Hippocampus | C57BL/6J mouse | Down |
| Study M130 | Type2 | CSDS + venlafaxine group vs. CSDS group | Prefrontal cortex | C57BL/6 mouse | Up |
| Study M131 | Type1 | SD group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M131 | Type1 | CRS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M131 | Type1 | LH group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M133 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M133 | Type2 | CUMS + XY-A group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M146 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M146 | Type2 | CUMS + venlafaxine group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M204 | Type1 | LPS group vs. control group | Hypothalamus | CD-1 mouse | Down |
| Study M460 | Type1 | depressed group vs. control group | Liver | Kunming mouse | Up |
| Study M463 | Type3 | DG group vs. control group | Prefrontal cortex | C57BL/6J mouse | Down |
| Study M473 | Type1 | high-fat diet group vs. control group | Prefrontal cortex | C57BL/6J mouse | Up |
| Study M478 | Type3 | ketamine group vs. control group | Hippocampus | C57BL/6J mouse | Down |
| Study M479 | Type1 | diabetic depression group vs. control group | Hypothalamus | Wistar rat | Down |
| Study M480 | Type1 | sleep deprivation group vs. control group | Urine | Wistar rat | Down |
| Study M486 | Type1 | CORT group vs. control group | PC12 cell medium | Rat | Down |
| Study M492 | Type1 | ACTH group vs. control group | Urine | Wistar rat | Down |
| Study M492 | Type2 | ACTH + memantine group vs. ACTH group | Urine | Wistar rat | Up |
| Study M492 | Type2 | ACTH + CGA group vs. ACTH group | Urine | Wistar rat | Up |
| Study M522 | Type1 | CUMS group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Unknown |
| Study M541 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M541 | Type2 | CUMS + venlafaxine group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M541 | Type2 | CUMS + high dose of AS group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M541 | Type2 | CUMS + low dose of AS group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M547 | Type1 | CUMS group vs. control group | Faece | Sprague-Dawley rat | Up |
| Study M556 | Type1 | sleep deprivation group vs. control group | Urine | Wistar rat | Down |
| Study M571 | Type1 | LPS group vs. control group | Hypothalamus | CD-1 mouse | Down |
| Study M573 | Type1 | CSDS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M577 | Type1 | male depression group vs. male control group, aged 20-29 | Plasma | Human | Unknown |
| Study M577 | Type1 | female depression group vs. female control group, aged 20-29 | Urine | Human | Unknown |
| Study M577 | Type1 | male depression group vs. male control group, aged 40-49 | Plasma | Human | Unknown |
| Study M577 | Type1 | female depression group vs. female control group, aged 40-49 | Plasma | Human | Unknown |
| Study M577 | Type1 | male depression group vs. male control group, aged 30-39 | Urine | Human | Unknown |
| Study M579 | Type1 | postpartum depression group vs. control group | Urine | Human | Up |
| Study M584 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M584 | Type2 | CUMS + high dose of Radix Bupleuri-Radix Paeoniae Alba herb pair group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M584 | Type2 | CUMS + high dose of Xiaoyaosan group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M584 | Type2 | CUMS + high dose of negative control treatment group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M584 | Type2 | CUMS + low dose of Xiaoyaosan group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M591 | Type1 | LPS group vs. control group | Prefrontal cortex | CD-1 mouse | Down |
| Study M602 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M610 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M610 | Type1 | CUMS group vs. control group | Heart | Sprague-Dawley rat | Up |
| Study M611 | Type1 | LPS group vs. control group | Liver | Sprague-Dawley rat | Unknown |
| Study M611 | Type1 | LPS group vs. control group | Serum | Sprague-Dawley rat | Unknown |
| Study M611 | Type1 | LPS group vs. control group | Kidney | Sprague-Dawley rat | Unknown |
| Study M611 | Type1 | LPS group vs. control group | Heart | Sprague-Dawley rat | Unknown |
| Study M629 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M629 | Type2 | CUMS + middle dose of coumaroylspermidine extract group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M631 | Type1 | CUMS group vs. control group | Serum | Kunming mouse | Down |
| Study M631 | Type2 | CUMS + high dose of iridoid-rich fraction of V. jatamansi group vs. CUMS group | Serum | Kunming mouse | Up |
| Study M636 | Type1 | CUMS group vs. control group | Faece | Sprague-Dawley rat | Down |
| Study M680 | Type1 | 5-fluorouracil group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M680 | Type2 | 5-fluorouracil + FMT group vs. 5-fluorouracil + sham FMT group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M685 | Type1 | SDS group vs. control group | Nucleus accumbens | C57BL/6J mouse | Up |
| Study M692 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M693 | Type1 | SDS group vs. control group | Plasma | C57BL/6J mouse | Down |
| Study M740 | Type1 | CUMS group vs. control group | Soleus muscle | Sprague-Dawley rat | Up |
| Study M740 | Type1 | CUMS group vs. control group | Gastrocnemius muscle | Sprague-Dawley rat | Up |
| Study M740 | Type2 | CUMS + endurance exercise group vs. CUMS group | Soleus muscle | Sprague-Dawley rat | Down |
| Study M756 | Type1 | depression group vs. control group | Serum | Human | Up |
| Study M788 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M790 | Type1 | CUMS group vs. control group | Liver | Sprague-Dawley rat | Up |
| Study M791 | Type1 | CUMS group vs. control group | Cecum | Sprague-Dawley rat | Down |
| Study M791 | Type2 | CUMS + Xiaoyaosan group vs. CUMS group | Cecum | Sprague-Dawley rat | Up |
| Study M815 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M815 | Type2 | CUMS + high dose of Radix Bupleuri–Radix Paeoniae Alba group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M828 | Type2 | ultrasonic radiation + intraperitoneally clomipramine group vs. ultrasonic radiation group | Frontal cortex | Wistar rat | Up |
| Study M839 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M843 | Type1 | CUMS group vs. control group | Faece | Cynomolgus monkey | Down |
| Study M844 | Type1 | CORT group vs. control group | PC12 cell | Rat | Down |
| Study M873 | Type1 | ovariectomy + CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M873 | Type2 | ovariectomy + CUMS + Xiang-Su volatile oil group vs. ovariectomy + CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M881 | Type1 | MDD group vs. control group | Plasma | Human | Up |
| Study M882 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M908 | Type3 | post-ketamine treatment vs. baseline | Plasma | Human | Up |
| Study M908 | Type3 | post-ketamine treatment vs. baseline | Cerebrospinal fluid | Human | Up |
| Study M921 | Type1 | CUMS group vs. control group | Liver | Sprague-Dawley rat | Down |
| Study M928 | Type1 | CUMS group vs. control group | Faece | C57BL/6 mouse | Down |
| Study M943 | Type2 | CUMS + middle dose of Acanthopanax senticosus Harms group vs. CUMS group | Liver | ICR mouse | Down |
| Study M950 | Type2 | probiotic group vs. placebo group | Faece | Human | Up |
| Study M962 | Type2 | 24h-post ketamine infusion vs. baseline | Plasma | Human | Up |
| Study M965 | Type1 | CUMS depression group vs. control group | Faece | Sprague-Dawley rat | Down |
| Study M971 | Type2 | CUMS + Tao-Hong-Si-Wu decoction group vs. CUMS group | Serum | Sprague-Dawley rat | Up |